Dr Soria speaks about locally advanced non-small cell lung cancer and the importance of personalised therapy. The development of drugs such as crizotinib, which are successful at treating a specific subset of patients, is significantly increasing the effectiveness of lung cancer treatment. Dr discusses tumour samples and the size of the sample that should be removed, the possibility of combining targeted agents and the importance of molecular profiling in targeted treatment.